1-4 of 4
Mark H. O'Hara
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C

Mark H. O’Hara, Opeyemi Jegede, Mark A. Dickson, Angela M. DeMichele, Richard Piekarz, Robert J. Gray, Victoria Wang, Lisa M. McShane, Lawrence V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Adedayo Onitilo, James V. Tricoli, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O’Dwyer, Alice P. Chen, Keith T. Flaherty
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF9.
https://doi.org/10.1158/1078-0432.CCR-24-0036
Published: 03 December 2024
View article titled, Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Open the PDF for Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C in another window
Includes: Supplementary data
Journal Articles

The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib

Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'Hara, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, Erica L. Carpenter, Katherine Nathanson, Susan M. Domchek, Kim A. Reiss
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (24): 5207–5216.
https://doi.org/10.1158/1078-0432.CCR-23-1467
Published: 15 December 2023
View article titled, The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
Open the PDF for The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib in another window
Includes: Supplementary data
Journal Articles

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer

Katelyn T. Byrne, Courtney B. Betts, Rosemarie Mick, Shamilene Sivagnanam, David L. Bajor, Daniel A. Laheru, E. Gabriela Chiorean, Mark H. O'Hara, Shannon M. Liudahl, Craig Newcomb, Cécile Alanio, Ana P. Ferreira, Byung S. Park, Takuya Ohtani, Austin P. Huffman, Sara A. Väyrynen, Andressa Dias Costa, Judith C. Kaiser, Andreanne M. Lacroix, Colleen Redlinger, Martin Stern, Jonathan A. Nowak, E. John Wherry, Martin A. Cheever, Brian M. Wolpin, Emma E. Furth, Elizabeth M. Jaffee, Lisa M. Coussens, Robert H. Vonderheide
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4574–4586.
https://doi.org/10.1158/1078-0432.CCR-21-1047
Published: 15 August 2021
View article titled, Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
Open the PDF for Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer in another window
Includes: Supplementary data
Journal Articles

A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma

Zijian Yang, Michael J. LaRiviere, Jina Ko, Jacob E. Till, Theresa Christensen, Stephanie S. Yee, Taylor A. Black, Kyle Tien, Andrew Lin, Hanfei Shen, Neha Bhagwat, Daniel Herman, Andrew Adallah, Mark H. O'Hara, Charles M. Vollmer, Bryson W. Katona, Ben Z. Stanger, David Issadore, Erica L. Carpenter
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13): 3248–3258.
https://doi.org/10.1158/1078-0432.CCR-19-3313
Published: 01 July 2020
View article titled, A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma
Open the PDF for A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma in another window
Includes: Supplementary data